Inventor

Thomas R. Gadek

Inventor

Oakland, CA, US

Overview

1978–2021

Patent span

Chemistry

Primary field (CPC C)

Patents· 63 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Dprimary

C07DHeterocyclic compounds30%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations24%

A61KPreparations for medical, dental or toiletry purposes15%

C07CAcyclic or carbocyclic compounds11%

Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests6%

C12NMicroorganisms or enzymes5%

C07KPeptides3%

G01NInvestigating or analysing materials by determining their chemical or physical properties3%

A61BDiagnosis2%

A61FFilters implantable into blood vessels1%

PatentTitleYear

11,028,077Crystalline pharmaceutical and methods of preparation and use thereof2021 10,960,087Compositions and methods for treatment of diabetic retinopathy2021 10,188,641Compositions and methods for treatment2019 9,447,077'Crystalline pharmaceutical and methods of preparation and use thereof'2016 9,045,457'Compositions and methods for treatment'2015 8,871,935'Crystalline pharmaceutical and methods of preparation and use thereof'2014 8,592,450'Compositions and methods for treatment of eye disorders'2013 8,367,701'Crystalline pharmaceutical and methods of preparation and use thereof'2013 8,168,655'Compositions and methods for treatment of eye disorders'2012 8,080,562'Crystalline pharmaceutical and methods of preparation and use thereof'2011 7,348,333'Cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists'2008 7,259,159'Guanidino derivatives as inhibitors of cell adhesion'2007 6,872,735'LFA-1 antagonist compounds'2005 6,867,208'Vitronectin receptor antagonists, their preparation and their use'2005 6,867,213'(2S)-2-(adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrhydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionic acid isopropyl ester, its preparation and its use'2005 6,762,190'Thienylalanine derivatives as inhibitors of cell adhesion'2004 6,747,016'Substituted purine derivatives as inhibitors of cell adhesion'2004 6,747,148'Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion'2004 6,743,800'Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them'2004 6,723,727'Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them'2004 6,667,318'LFA-1 antagonist compounds'2003 6,660,728'Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists'2003 6,602,878'Acylquanidine derivatives, method for preparing same, application as medicines and pharmaceutical compositions containing them'2003 6,586,442'Benzofurane derivatives, their preparation process, their use as medicaments and the pharmaceutical compositions containing them'2003 6,566,366'Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists'2003 6,500,815'Substituted 11.beta steroid derivatives, method for preparing same and intermediates of said method, use as medicine and compositions containing them'2002 6,492,356'Acylguanidine derivatives as inhibitors of bone resorption and as vitronectin receptor antagonists'2002 6,482,821'Vitronectin receptor antagonists, their preparation and their use'2002 6,458,801'Benzofurane derivatives, preparation method, use as medicines and pharmaceutical compositions containing same'2002 6,459,001'Tricyclic compounds, their preparation process and the intermediates of this process, their use as medicaments and the pharmaceutical compositions containing them'2002 6,399,620'Cycloalkyl derivatives as inhibitors of bone resporption and vitronectin receptor antagonists'2002 6,391,904'Iminoguanidine derivatives, preparation method, use as medicines'2002 6,387,395'N-1, (1-1) -dialkyloxy - and N- 1, (1-1) -dialkenyloxy- alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor'2002 6,387,895'Vitronectin receptor antagonists, their preparation and their use'2002 6,344,439'Agents for promoting bone formation'2002 6,340,679'Guanidine derivatives as inhibitors of cell adhesion'2002 6,339,082'Tricyclic compounds, preparation method and said method intermediates, application as medicines and pharmaceutical compositions containing same'2002 6,313,119'Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion'2001 6,277,845'Hydrazono-benzazulene derivatives, pharmaceutical compositions and intermediates'2001 6,221,907'Tricyclic compounds having activity specific for integrins, particularly alphanubeta3 integrins, method for preparing same, intermediates therefor, use of said compounds as drugs, and pharmaceutical compositions containing same'2001 6,218,387'Vitronectin receptor anatagonists, their preparation and their use'2001 6,207,663'Vitronectin receptor antagonists, their preparation and use'2001 6,194,380'Agents for promoting bone formation'2001 6,011,045'Vitronectin receptor antagonists, their preparation and their use'2000 6,005,117'Imino compounds, process for their preparation and their use as victronectin antagonists'1999 5,990,145'Vitronectin receptor antagonists, their preparation and their use'1999 5,756,452'Platelet aggregation inhibitors having high specificity for GP II.sub.b III.sub.a'1998 5,674,863'Nonpeptidyl integrin inhibitors having specificity for the GPII.sub.b III.sub.a receptor'1997 5,674,865'Nonpeptidyl integrin inhibitors having specificity for the GPII.sub.b III.sub.a'1997 5,663,166'Nonpeptidyl integrin inhibitors having specificity for the GPII.sub.b III.sub.a receptor'1997 5,622,712'N-[.omega., (.omega.-1)-dialkyloxy]- and N-[.omega., (.omega.-1)-dialkenyloxy]-alk-1-yl-N, N, N-tetrasubstituted ammonium lipids and uses therefor'1997 5,565,449'Nonpeptidyl integrin inhibitors having specificity for the GPII.sub.b III.sub.a receptor'1996 5,550,289'N-(1,(1-1)-dialkyloxy)-and N-(1,(1-1)-dialkenyloxy alk-1-yl-N-N,N-tetrasubstituted ammonium lipids and uses therefor'1996 5,545,412'N-[1, (1-1)-dialkyloxy]-and N-[1, (1-1)-dialkenyloxy]-alk-1-yl-n,n,n-tetrasubstituted ammonium lipids and uses therefor'1996 5,493,007'Platelet aggregation inhibitors having high specificity for GPIIBIIIA'1996 5,403,836'Benzazepine platelet aggregation inhibitors having specificity for the GPII.sub.b III.sub.a receptor'1995 5,366,737'N-[.omega.,(.omega.-1)-dialkyloxy]- and N-[.omega.,(.omega.-1)-dialkenyloxy]-alk-1-yl-N,N,N,-tetrasubstituted ammonium lipids and uses therefor'1994 5,250,679'Nonpeptidyl platelet aggregation inhibitors having specificity for the GPII.sub.b III.sub. receptor'1993 5,208,036'N-(.omega., (.omega.-1)-dialkyloxy)- and N-(.omega., (.omega.-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor'1993 5,049,386'N-.omega.,(.omega.-1)-dialkyloxy)- and N-(.omega.,(.omega.-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor'1991 4,946,787'N-(.omega.,(.omega.-1)-dialkyloxy)- and N-(.omega.,(.omega.-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor'1990 4,897,355'N[.omega.,(.omega.-1)-dialkyloxy]- and N-[.omega.,(.omega.-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor'1990 4,104,308'Synthesis of squaric acid'1978

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1978Based in Boulder, CO, US· patent location history

1990–2021Based in Oakland, CA, US· patent location history

1993–2007Patents assigned to GENENTECH INC (35)· patent assignee history

1999–2005Patents assigned to HOECHST AG (9)· patent assignee history

2001–2008Patents assigned to AVENTIS PHARMA SA (9)· patent assignee history

2001–2005Patents assigned to AVENTIS PHARMA GMBH (8)· patent assignee history

2002Based in Palo Alto, CA, US· patent location history

2011–2019Patents assigned to SARCODE BIOSCIENCE INC (8)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
GENENTECH INC	35	1993–2007
AVENTIS PHARMA SA	9	2001–2008
HOECHST AG	9	1999–2005
AVENTIS PHARMA GMBH	8	2001–2005
SARCODE BIOSCIENCE INC	8	2011–2019

Locations

Location	Patents	Span
Oakland, California, US	61	1990–2021
Palo Alto, California, US	1	2002
Boulder, CO, US	1	1978